IENTC Telecomunicaciones Selects VectorMax Corporation to Deliver IP Live Linear with SVOD to Support Growth in Mexico
16.6.2020 16:17:00 EEST | Business Wire | Press release
IENTC Telecomunicaciones, an internet and television service provider operating in the Mexican market, today announced it is launching VectorMax’s turn-key IPTV Platform as the software to support its new television product. Serving the market for more than 10 years, IENTC Telecomunicaciones’ new service augmenting its consumer offering reflects the growing shift from broadcast television to IP delivery of live linear TV.
This marks the first commercial deployment of an all software solution enabling operators to transition from broadcast to online delivery of live linear television without having to upgrade their network architecture. The software leverages $73M of R&D from teams out of MIT, IBM Labs, Bell Labs, DARPA and MPEG related projects to deliver multicast live linear as a turn-key, fully integrated, multicast software platform for cable operators, telcos, and high-speed access providers.
“Operators need to transition and support their entertainment experiences to remain relevant and competitive,” said Peter von Schlossberg, VectorMax’s President Global Product. “Our operators are searching for solutions to deliver a live linear consumer experience side-by-side with SVOD offerings from Netflix, Hulu, Amazon, Google, etc. VectorMax developed a unique software solution that capitalizes on existing infrastructure and networks to deliver high-quality live linear broadcast & other IP services.
“Transitioning to online delivery of live linear can be daunting, but VectorMax’s software platform allowed us to quickly see our consumer offering ingested and delivered in multicast by the VectorMax software. Our own branded Streaming Media Player apps on Amazon FireTV, Roku, Android STBs, Smart TVs and iOS were live within weeks. VectorMax’s ‘show-me’ sales strategy enabled us to easily determine they were the best fit to support the growing demands of our customers,” said Carlos Arguimbau, CEO of IENTC.
VectorMax’s ability to execute technological and marketing solutions with minimal disruption to our existing operations assured us that they were an important resource to navigate new market dynamics. The end product is a win-win for both IENTC and our customers,” said Arguimbau.
IENTC’s new +TV service is bolstered by a recent study from Hub Entertainment Research. The study found that the average number of television services accessed online per viewer in the US in the past 24 months reflected a rise of over 50%. That number is expected to trend globally. IENTC is also tracking the Hub findings reflecting pay-TV subscribers who have used an operator provided set-top box to watch streaming services tend to keep using it; 58% do so to access Netflix, 61% for Amazon, and 57% for Hulu.
“These findings are a key validation of providers’ efforts to aggregate streaming services as another way to create value in the set-top box and reduce cord-cutting”, said von Schlossberg.“VectorMax deployed our Platform in December which is now being expanded to a wider area of IENTC’s footprint in Mexico. Strategically, we are positioned to help cable companies and telecoms address this shift and to market new services as easily as flicking on a switch. The VectorMax Platform is slated for a roll-out to additional customers starting Q3 2020”.
About VectorMax Corporation
VectorMax’s pioneering of technologies that increase the efficiencies in delivering IP video over large scale, fully developed, and imperfect networks, solves the evolution of live linear broadcast television to on-network online delivery. The Company holds 102 worldwide patents grounded in software-based IP transport delivery technologies.
Supported with $73 million of R&D and twelve years of intensive research and development, conducted by a development team with MIT, IBM Labs, Bell Labs, DARPA & MPEG credentials, the Company delivers a complete end to end platform comprised of multiple modules designed to work together to deliver IPTV to large scale audiences over less than optimal networks within bandwidth constrained and limited infrastructure environments. The carrier requires no other third-party component to ingest, encode, manage and deliver the immersive experience that 2020 subscribers expect. Discover more at www.vectormax.com.
About IENTC Telecomunicaciones
IENTC Telecomunicaciones is a company with more than 10 years in the telecommunications industry located in the central zone of Mexico. With high-speed internet that is offered through its’ own fiber-optic network, providing best in class service and a customer experience that guarantees business is always connected. IENTC has the most advanced technology available in the market, which enables the offering of additional services such as Mobile phone, Virtual PBX, Smart Internet, and Television services among others. Discover more at ientc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005227/en/
Contact information
Bryen Aoyama
+1 (310) 403-2579
bryen@vectormax.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom